DHHS Guidelines 2022
Recommended as an initial regimen for most PLHIV (AI)* and as a good option for virologically suppressed patients who have no evidence of resistance to either drug
Exclusions for treatment-naïve patients:
- HIV viral load >500,000 copies/mL
- HBV co-infection
- Where ART is to be started before the results of HIV genotype resistance testing for reverse transcriptase or HBV testing are available
*Rating of recommendations: A=strong; B=moderate; C=optional. Rating of evidence: I=data from randomised controlled trials; II=data from well-designed non-randomised trials, observational cohort studies with long-term clinical outcomes, relative bioavailability/bioequivalence studies or regimen comparisons from randomised switch studies; III=expert opinion.